Zealand chief medical officer on abandoned Boehringer collaboration: "We need to look at the data"
Boehringer Ingelheim called off a collaboration to develop amylin analog drugs for obesity and diabetes with Zealand Pharma on Friday. Zealand must now decide whether to develop an amylin analog itself, or scrap the project.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.